A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Inês Soares de Pinho, Miguel Esperança-Martins, Bárbara Machado, Sara Dâmaso, Raquel Lopes Brás, Guilhermina Cantinho, Isabel Fernandes, Luís Costa

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)

Abstract

Radium-223 dichloride (Ra223) is the first targeted alpha agent approved for treating metastatic castration-resistant prostate cancer (mCRPC) with bone-exclusive disease. A benefit in overall survival and time to the first symptomatic skeletal-related event was shown in the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. However, this trial did not describe a bone scan response to Ra223, and there is no universal consensus about how it should be monitored. Furthermore, a scintigraphy flare phenomenon may lead to false-positive tracer uptake in responsive cases, thereby misleading the interpretation of imaging results. We present the case of a 67-year-old male with mCRPC and exclusive bone disease treated with Ra223. The bone scintigraphy after the end of the treatment showed an apparent aggravation of the lesions, corresponding to a flare phenomenon, with an almost complete resolution after three months. The patient maintained a scintigraphic response for seven months.

Original languageEnglish
Pages (from-to)e53637
JournalCureus
Volume16
Issue number2
DOIs
Publication statusPublished - Feb 2024

Keywords

  • bone disease
  • response
  • flare
  • radium-223
  • prostate cancer

Fingerprint

Dive into the research topics of 'A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.

Cite this